8-K: Omeros Announces FDA Acceptance of Narsoplimab BLA Resubmission for TA-TMA Treatment

The FDA has accepted Omeros' resubmitted Biologics License Application (BLA) for narsoplimab in treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), setting a target action date in late September 2025.

Summary

• Omeros Corporation announced that the FDA has accepted the resubmission of its BLA for narsoplimab to treat TA-TMA.
• The FDA has assigned a target action date in late September 2025 under the Prescription Drug User Fee Act (PDUFA).
• The resubmission includes analyses showing statistically significant improvements in survival associated with narsoplimab treatment compared to an external control group.
• The BLA also contains data from Omeros' expanded access program, which treated adult and pediatric TA-TMA patients with narsoplimab.
• Omeros is responding to information requests from the FDA and expects an interactive review.
• The company is also preparing a marketing authorization application (MAA) for narsoplimab in TA-TMA for submission to the European Medicines Agency later this quarter.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the FDA's acceptance of the BLA resubmission and the potential for narsoplimab to become the first approved treatment for TA-TMA. However, risks remain regarding regulatory approval and commercialization.

Positives

• The FDA's acceptance of the BLA resubmission is a positive step toward potential approval of narsoplimab for TA-TMA.
• The assigned PDUFA date provides a timeline for the FDA's decision.
• Clinical data included in the resubmission demonstrates statistically significant survival improvements with narsoplimab.
• The preparation of an MAA for submission to the EMA expands the potential market for narsoplimab.

Risks

• The FDA may not ultimately approve the BLA for narsoplimab.
• The EMA may not approve the MAA for narsoplimab.
• Regulatory processes could face unanticipated delays or require additional data.
• Omeros' financial condition could impact its ability to commercialize narsoplimab if approved.
• There are risks associated with the manufacture and supply of narsoplimab.

Future Outlook

Omeros anticipates an interactive review process with the FDA and is preparing to submit an MAA to the EMA later this quarter. The company expects to potentially commercialize narsoplimab if approved by the FDA or EMA.

Management Comments

• Omeros expects an interactive review by FDA.
• Omeros is also preparing a marketing authorization application (MAA) for narsoplimab in TA-TMA, which is targeted for submission to the European Medicines Agency later this quarter.

Industry Context

The announcement is significant because there is no approved therapy or standard of care for TA-TMA, a serious complication of stem cell transplantation. Narsoplimab, if approved, would be the first targeted treatment for this condition.

Comparison to Industry Standards

• There are currently no approved therapies for TA-TMA, making narsoplimab a potential first-in-class treatment.
• The 40-percent incidence of TA-TMA in allogeneic stem cell transplant populations highlights the unmet medical need.
• Mortality rates exceeding 90 percent in severe cases of TA-TMA underscore the urgency for effective treatments.

Stakeholder Impact

• Positive for patients with TA-TMA, who may gain access to a new treatment option.
• Positive for Omeros shareholders, as approval of narsoplimab could increase the company's revenue and value.
• Positive for Omeros employees, as successful commercialization of narsoplimab could lead to job growth and stability.

Next Steps

• Omeros will continue to respond to information requests from the FDA.
• Omeros will prepare and submit the MAA to the EMA later this quarter.
• The FDA will review the BLA, with a target action date in late September 2025.

Key Dates

Keywords

narsoplimab, TA-TMA, Omeros, FDA, BLA, MAA, hematopoietic stem cell transplant, thrombotic microangiopathy, PDUFA, EMA